Understanding PD Prevalence
Understanding how many people are living with PD is critical to advancing research and care. To address it, PDF is investing $250,000 in the PD Prevalence Project.Learn More
Your Donations Make a Difference
Your support makes the research of Dr. Hess and Dr. Earhart possible, allowing us to learn about the role of genetics and the potential of exercise in Parkinson's.
Watch Our Video & Learn More
VIDEO: FDA Approves Nuplazid™ for Treatment of Psychosis in Parkinson’s
May 3, 2016
The Parkinson’s Disease Foundation (PDF) alerts the community that pimavanserin (Nuplazid™) has been approved by the US Food and Drug Administration (FDA) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. The drug’s manufacturer, Acadia Pharmaceuticals Inc., announced the approval on April 29. Pimavanserin is the first drug indicated specifically to treat symptoms of psychosis in Parkinson’s. See this article, and a new video from Dr. James Beck, Vice President, Scientific Affairs at PDF, to learn more.
PDF Research: Conference on Non-Pharma Ways to Maintain Cognition
Friday, June 3 (Chicago, IL)
The conference, led by Jennifer Goldman, M.D., M.S., of the PDF Research Center at Rush University Medical Center, Chicago, IL, is funded as part of the PDF Community Choice Research Awards, which seek insight from the patient community about its priorities for research. PDF is gathering leaders in Parkinson’s as well as specialists from related areas to assess where we are in understanding and treating cognition, and what needs to be done to move the field forward.